FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104961772> ?p ?o ?g. }

• W2104961772 endingPage "267" @default.
• W2104961772 startingPage "262" @default.
• W2104961772 abstract "Background Hemangioblastomas account for up to 2.5% of all intracranial tumors. They may occur sporadically or as a part of the multisystem genetic syndrome of Von Hippel-Lindau syndrome (VHL). Patients with VHL are also at an increased risk of developing clear cell renal cell carcinoma (ccRCC). Distinguishing hemangioblastomas from metastatic ccRCC to the central nervous system (CNS) can be challenging at times when based solely on hematoxylin and eosin-stained sections. We propose an immunohistochemistry (IHC) panel of combination of PAX2, PAX8, and inhibin A as a helpful approach in distinguishing the 2 lesions. Design Archival tissues from 20 hemangioblastomas and 16 ccRCCs metastatic to the CNS were retrieved from our surgical pathology files (2001 to 2010). IHC for PAX2, PAX8, and inhibin A was performed on routine or tissue microarray sections using standard IHC protocol. The intensity of nuclear staining was evaluated for each marker and was assigned an incremental 0, 1+, 2+, and 3+ score. The extent of staining was categorized as focal (<25%), multifocal (25% to 75%), or diffuse (>75%). Result (1) Hemangioblastoma: The Von Hippel-Lindau syndrome was diagnosed in 4 of 16 (25%) patients, 2 of whom developed multiple hemangioblastomas. All 20 (100%) hemangioblastomas were positive for inhibin A (cytoplasmic). The staining intensity was moderate or strong (2+ or 3+) in 19 cases (95%), all of which were multifocal or diffuse in extent. Nuclear PAX2 staining was present in 1 of 19 evaluable lesions (5%), whereas PAX8 staining was not present in any of the 20 examined lesions. (2) Metastatic ccRCC to the CNS: Fourteen of 16 (88%) examined ccRCCs were positive for PAX2, whereas 15 of 16 (94%) lesions showed PAX8 staining. None of 16 (0%) examined ccRCCs were positive for inhibin A. Conclusions We propose the use of the combination of PAX2, PAX8, and inhibin A as a helpful ancillary IHC panel to resolve the differential diagnosis of hemangioblastoma versus metastatic ccRCC. The immunoprofile of PAX2(+) or PAX8(+) and inhibin A(−) supports the diagnosis of metastatic ccRCC with a sensitivity of 94%, specificity of 100%, and positive predictive value of 100%. The PAX2(−), PAX8(−), and inhibin A(+) profile supports the diagnosis of hemangioblastoma with a sensitivity of 95%, specificity of 100%, and positive predictive value of 100%." @default.
• W2104961772 created "2016-06-24" @default.
• W2104961772 creator A5008207753 @default.
• W2104961772 creator A5009195048 @default.
• W2104961772 creator A5013809220 @default.
• W2104961772 creator A5026609192 @default.
• W2104961772 creator A5047848345 @default.
• W2104961772 creator A5056103345 @default.
• W2104961772 creator A5064618296 @default.
• W2104961772 creator A5083089728 @default.
• W2104961772 date "2011-02-01" @default.
• W2104961772 modified "2023-09-27" @default.
• W2104961772 title "PAX2(−)/PAX8(−)/Inhibin A(+) Immunoprofile in Hemangioblastoma" @default.
• W2104961772 cites W1480878209 @default.
• W2104961772 cites W172539724 @default.
• W2104961772 cites W1852342283 @default.
• W2104961772 cites W1863917498 @default.
• W2104961772 cites W1973432828 @default.
• W2104961772 cites W1975807922 @default.
• W2104961772 cites W1980794884 @default.
• W2104961772 cites W1999767254 @default.
• W2104961772 cites W2027240662 @default.
• W2104961772 cites W2031724190 @default.
• W2104961772 cites W2039004437 @default.
• W2104961772 cites W2046103294 @default.
• W2104961772 cites W2061645064 @default.
• W2104961772 cites W2077208354 @default.
• W2104961772 cites W2090854331 @default.
• W2104961772 cites W2127316885 @default.
• W2104961772 doi "https://doi.org/10.1097/pas.0b013e3182064d11" @default.
• W2104961772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21263247" @default.
• W2104961772 hasPublicationYear "2011" @default.
• W2104961772 type Work @default.
• W2104961772 sameAs 2104961772 @default.
• W2104961772 citedByCount "54" @default.
• W2104961772 countsByYear W21049617722012 @default.
• W2104961772 countsByYear W21049617722013 @default.
• W2104961772 countsByYear W21049617722014 @default.
• W2104961772 countsByYear W21049617722015 @default.
• W2104961772 countsByYear W21049617722016 @default.
• W2104961772 countsByYear W21049617722017 @default.
• W2104961772 countsByYear W21049617722018 @default.
• W2104961772 countsByYear W21049617722019 @default.
• W2104961772 countsByYear W21049617722021 @default.
• W2104961772 countsByYear W21049617722022 @default.
• W2104961772 countsByYear W21049617722023 @default.
• W2104961772 crossrefType "journal-article" @default.
• W2104961772 hasAuthorship W2104961772A5008207753 @default.
• W2104961772 hasAuthorship W2104961772A5009195048 @default.
• W2104961772 hasAuthorship W2104961772A5013809220 @default.
• W2104961772 hasAuthorship W2104961772A5026609192 @default.
• W2104961772 hasAuthorship W2104961772A5047848345 @default.
• W2104961772 hasAuthorship W2104961772A5056103345 @default.
• W2104961772 hasAuthorship W2104961772A5064618296 @default.
• W2104961772 hasAuthorship W2104961772A5083089728 @default.
• W2104961772 hasConcept C104317684 @default.
• W2104961772 hasConcept C124224327 @default.
• W2104961772 hasConcept C125473707 @default.
• W2104961772 hasConcept C142724271 @default.
• W2104961772 hasConcept C193270364 @default.
• W2104961772 hasConcept C204232928 @default.
• W2104961772 hasConcept C2777472916 @default.
• W2104961772 hasConcept C2778460572 @default.
• W2104961772 hasConcept C2778560582 @default.
• W2104961772 hasConcept C2781278892 @default.
• W2104961772 hasConcept C55493867 @default.
• W2104961772 hasConcept C71924100 @default.
• W2104961772 hasConcept C74864618 @default.
• W2104961772 hasConcept C86339819 @default.
• W2104961772 hasConcept C86803240 @default.
• W2104961772 hasConceptScore W2104961772C104317684 @default.
• W2104961772 hasConceptScore W2104961772C124224327 @default.
• W2104961772 hasConceptScore W2104961772C125473707 @default.
• W2104961772 hasConceptScore W2104961772C142724271 @default.
• W2104961772 hasConceptScore W2104961772C193270364 @default.
• W2104961772 hasConceptScore W2104961772C204232928 @default.
• W2104961772 hasConceptScore W2104961772C2777472916 @default.
• W2104961772 hasConceptScore W2104961772C2778460572 @default.
• W2104961772 hasConceptScore W2104961772C2778560582 @default.
• W2104961772 hasConceptScore W2104961772C2781278892 @default.
• W2104961772 hasConceptScore W2104961772C55493867 @default.
• W2104961772 hasConceptScore W2104961772C71924100 @default.
• W2104961772 hasConceptScore W2104961772C74864618 @default.
• W2104961772 hasConceptScore W2104961772C86339819 @default.
• W2104961772 hasConceptScore W2104961772C86803240 @default.
• W2104961772 hasIssue "2" @default.
• W2104961772 hasLocation W21049617721 @default.
• W2104961772 hasLocation W21049617722 @default.
• W2104961772 hasOpenAccess W2104961772 @default.
• W2104961772 hasPrimaryLocation W21049617721 @default.
• W2104961772 hasRelatedWork W2011760975 @default.
• W2104961772 hasRelatedWork W2034555737 @default.
• W2104961772 hasRelatedWork W2055408636 @default.
• W2104961772 hasRelatedWork W2057491139 @default.
• W2104961772 hasRelatedWork W2104961772 @default.
• W2104961772 hasRelatedWork W2135269189 @default.
• W2104961772 hasRelatedWork W2382030540 @default.
• W2104961772 hasRelatedWork W2768723556 @default.

• next